Close Menu

NEW YORK — PathSensors said on Thursday that it has signed an agreement expanding its exclusive license to a Massachusetts Institute of Technology-developed pathogen detection technology to include clinical applications.

According to the Baltimore-based company, its first clinical application of the technology will be for SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.